Table 3.
Characteristics of MABSC and MAC positive CF patients in Scandinavia.
| Characteristic at time of first positive isolate | Patients with MABSC |
Patients with MAC |
p-Value |
|---|---|---|---|
| (n = 70) | (n = 51) | ||
| Female, % | 52 | 38 | 0.13 |
| Median age (IQR), y | 17 (12–21) | 22 (15–32) | < 0.01 |
| Homozygous for F508del mutation, % | 64 | 68 | 0.63 |
| Median %FEV1 of pred. (IQR) | 83 (57–96) | 76 (62–95) | 0.18 |
| Median BMI kg/m2 (IQR) | 19 (17–21) | 20 (19–23) | 0.11 |
| Z-BMI | − 0.1 (− 1.0–0.6) | − 0.4 (− 1.0–0.5) | 0.77 |
| Pancreatic insufficiency, % | 94 | 84 | 0.07 |
| CFRD, % | 22 | 18 | 0.62 |
| Chronic Gram negative infection, % | 59 | 69 | 0.33 |
| Aspergillus infection a, % | 48 | 55 | 0.13 |
| ABPA, % | 25 | 21 | 0.64 |
| Azithromycin treatment, % | 18 | 25 | 0.19 |
| Oral or IV steroid treatment, % | 10 | 7 | 0.63 |
MABSC = M. abscessus complex; MAC = M. avium complex; NTM = nontuberculous mycobacteria;
IQR = interquartile range, CFRD = cystic fibrosis related diabetes.
a
Defined as having positive Aspergillus cultures at least 6 months of a calendar year; ABPA = allergic bronchopulmonary aspergillosis, defined according to consensus criteria [33].